Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1 Completed 18 enrolled Wake Forest University Health Sciences National Cancer Institute (NCI) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Angiotensin-(1-7) may stop the growth of solid tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of angiotensin-(1-7) in treating patients with metastatic or unresectable solid tumors.

Timeline

Start: 2007-03
Primary completion: 2009-10
Completion: 2009-10

Publications

Results Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009 Dec 1;15(23):7398-404. doi: 10.1158/1078-0432.CCR-09-1957. Epub 2009 Nov 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	talfirastide	Peptide	—	Subcutaneous

Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors

Summary

Timeline

Publications

Drugs

Indications